COLL 株価分析 — COLLEGIUM PHARMACEUTICAL INC (Healthcare >> Drug Manufacturers - Specialty & Generic)
COLL に関するよくある質問
COLLのPER(株価収益率)は?
COLLEGIUM PHARMACEUTICAL INC(COLL)は現在PER 15.57倍で取引されています。
COLLのROE(自己資本利益率)は?
COLLEGIUM PHARMACEUTICAL INCのROEは23.99%です。
COLLの配当利回りは?
COLLEGIUM PHARMACEUTICAL INCの配当利回りは0.00%です。
COLLの品質スコア(Quality Score)は?
当社のAIはCOLLの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
COLLは今が買い時ですか?
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
COLLはどのセクターに属しますか?
COLLEGIUM PHARMACEUTICAL INCはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NASDAQ市場)
COLL AI Analysis Summary
Our AI summary for COLL: COLLEGIUM PHARMACEUTICAL INC (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 15.57, ROE of 23.99%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 35.39
Price
-0.59
(-1.64%)
Day Change
|
|
|---|
COLL, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
1457
|
| Magic Formula Rank by ROE |
1457
|
| Magic Formula Rank by ROIC |
820
|
| Price | 35.39 |
| PBV / Sector |
3.74 / 3.22
|
| Earning Per Share | 2.27 |
| PE / Sector |
15.57 / 29.79
|
| PEG or PE/Growth / Sector |
-0.22 / 0.13
|
| Average 1M Daily Value |
13.25 M
GREAT
|
| Average 1W Daily Value |
10.21 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
66% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:39 |
| Symbol | COLL |
| Name | COLLEGIUM PHARMACEUTICAL INC |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 32.43 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,166.97 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 100 Technology Center Drive, Stoughton, MA, United States, 02072
Phone: 781 713 3699
Website: https://www.collegiumpharma.com
Employees: 423
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google